A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

S Margolin; L Carlsson; M Hellström; P Karlsson; E Lidbrink; B Linderholm; H Lindman; Per Malmström; D Sköld Pettersson; J Bergh

doi:10.1016/S1359-6349(08)70548-2

A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

S Margolin, L Carlsson, M Hellström, P Karlsson, E Lidbrink, B Linderholm, H Lindman, Per Malmström, D Sköld Pettersson, J Bergh

Breastcancer-genetics

Research output: Contribution to journal › Published meeting abstract › peer-review

Original language	English
Pages (from-to)	116-117
Journal	European Journal of Cancer Supplements
Volume	6
Issue number	7
DOIs	https://doi.org/10.1016/S1359-6349(08)70548-2
Publication status	Published - 2008
Event	EBCC-6, European Breast Cancer Conference, 2008 - Berlin, Germany Duration: 2008 Apr 14 → 2008 Apr 19

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1359-6349(08)70548-2

Cite this

Margolin, S., Carlsson, L., Hellström, M., Karlsson, P., Lidbrink, E., Linderholm, B., Lindman, H., Malmström, P., Sköld Pettersson, D., & Bergh, J. (2008). A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. European Journal of Cancer Supplements, 6(7), 116-117. https://doi.org/10.1016/S1359-6349(08)70548-2

@article{e53174a6c67343f29c01797a8966fc76,

title = "A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer",

author = "S Margolin and L Carlsson and M Hellstr{\"o}m and P Karlsson and E Lidbrink and B Linderholm and H Lindman and Per Malmstr{\"o}m and {Sk{\"o}ld Pettersson}, D and J Bergh",

year = "2008",

doi = "10.1016/S1359-6349(08)70548-2",

language = "English",

volume = "6",

pages = "116--117",

journal = "European Journal of Cancer Supplements",

issn = "1359-6349",

publisher = "Elsevier",

number = "7",

note = "EBCC-6, European Breast Cancer Conference, 2008 ; Conference date: 14-04-2008 Through 19-04-2008",

}

Margolin, S, Carlsson, L, Hellström, M, Karlsson, P, Lidbrink, E, Linderholm, B, Lindman, H, Malmström, P, Sköld Pettersson, D & Bergh, J 2008, 'A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer', European Journal of Cancer Supplements, vol. 6, no. 7, pp. 116-117. https://doi.org/10.1016/S1359-6349(08)70548-2

A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. / Margolin, S; Carlsson, L; Hellström, M et al.
In: European Journal of Cancer Supplements, Vol. 6, No. 7, 2008, p. 116-117.

Research output: Contribution to journal › Published meeting abstract › peer-review

TY - JOUR

T1 - A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

AU - Margolin, S

AU - Carlsson, L

AU - Hellström, M

AU - Karlsson, P

AU - Lidbrink, E

AU - Linderholm, B

AU - Lindman, H

AU - Malmström, Per

AU - Sköld Pettersson, D

AU - Bergh, J

PY - 2008

Y1 - 2008

U2 - 10.1016/S1359-6349(08)70548-2

DO - 10.1016/S1359-6349(08)70548-2

M3 - Published meeting abstract

SN - 1359-6349

VL - 6

SP - 116

EP - 117

JO - European Journal of Cancer Supplements

JF - European Journal of Cancer Supplements

IS - 7

T2 - EBCC-6, European Breast Cancer Conference, 2008

Y2 - 14 April 2008 through 19 April 2008

ER -

Margolin S, Carlsson L, Hellström M, Karlsson P, Lidbrink E, Linderholm B et al. A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. European Journal of Cancer Supplements. 2008;6(7):116-117. doi: 10.1016/S1359-6349(08)70548-2